IL11RA
Interleukin-11 receptor subunit alpha
As of the edition of 20 October 2026, IL11RA (interleukin-11 receptor subunit alpha, UniProt Q14626) has 2 drugs tested at it and 3 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q14626
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 5
- Disease areas
- Blood and lymph; Inherited and neonatal; Immune system; Cancer; Eye; Heart and blood vessels; Hormones; Lungs and airways
- Registered trials of its drugs
- 10
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Status not established | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Oprelvekin | Marketed | Phase 2 | Ended 2009 |
| LASN01 | Status not established | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Undetermined | 3 |
| Total on the list | 3 |